CD30: an important new target in hematologic malignancies

Leuk Lymphoma. 2011 Sep;52(9):1641-54. doi: 10.3109/10428194.2011.574761. Epub 2011 May 27.


CD30 is abundantly and selectively expressed on the surface of Hodgkin Reed-Sternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid malignancies as well as on several non-lymphoid malignancies including selected germ cell tumors. Expression of CD30 on normal cells is highly restricted, thereby allowing differential targeting of malignant cells. CD30, a member of the tumor necrosis factor (TNF)-receptor family has pleiotropic biologic functions, and antibodies targeting CD30 and other TNF family receptors can exhibit both agonistic and antagonistic signaling functions. Recently, antibody-drug conjugates targeting CD30, such as brentuximab vedotin, have shown striking activity in phase I and II trials, with manageable toxicity. This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / genetics
  • Hematologic Neoplasms / metabolism
  • Humans
  • Ki-1 Antigen / antagonists & inhibitors*
  • Ki-1 Antigen / immunology
  • Ki-1 Antigen / metabolism
  • Molecular Targeted Therapy


  • Antibodies, Monoclonal
  • Ki-1 Antigen